Re: Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study

Eur Urol. 2022 Feb;81(2):216. doi: 10.1016/j.eururo.2021.11.003. Epub 2021 Nov 20.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antineoplastic Agents, Immunological* / therapeutic use
  • Carcinoma, Renal Cell* / drug therapy
  • Female
  • Humans
  • Kidney Neoplasms* / drug therapy
  • Male
  • Nivolumab / therapeutic use
  • Radiosurgery*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab